The minority of tumors that are PD-L1 positive also express higher rates of other biomarkers including BRAF, BRCA2, RNF43, TP53, and TOP2A mutations, with increased tumor mutational burden and increased microsatellite instability, which could lead to more therapeutic options for patients with PD-L1-positive tumors [118]. Here, CD274 is linked to neoplasm.